Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in developing adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinsons disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a worldwide licensing agreement with Ramot, the technology transfer company of the Tel Aviv University.
BCLI's NurOwn technology, an autologous adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells into specialized neuron-supporting cells. It also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center.
Brainstorm Cell Therapy was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. BCLI was founded in 2000 and is based in New York, New York.
July 19, 2024
RegMed Investors (RMi) Closing Bell: The Humpty-Dumpty market and sector had a great fall
July 19, 2024
RegMed Investors (RMi) Closing Bell: The Humpty-Dumpty market and sector had a great fall
July 18, 2024
RegMed Investors (RMi) Closing Bell: increasing turbulence
July 18, 2024
RegMed Investors (RMi) Closing Bell: increasing turbulence
July 17, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy sector equities tank
July 17, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy sector equities tank
July 16, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy sector equities ride the waves
July 16, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy sector equities ride the waves
July 15, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy sector continues its momentum
July 15, 2024
RegMed Investors (RMi) Closing Bell: cell and gene therapy sector continues its momentum
35 companies, 1 interpreter!
Insight, foresight and recommendation
Brainstorm Cell Therapeutics (BCLI) – January '18 openaed at $3.65, dropping in February to $3.45 and continuing to drop to $3.10 on 2/12 and $3.19 on 2/16. Even with their on-going trial, I have a problem with theor corporate transparency ... tey revolve on news and the pricing falls back ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors